Citadel Advisors
DTIL icon

Citadel Advisors’s Precision BioSciences DTIL Stock Holding History

Citadel Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-103
Closed -$1.63K – 14459
2023
Q2 		$1.63K Sell
103
-300
-74% -$6.86K ﹤0.01% 13896
2023
Q1 		$9.12K Buy
403
+23
+6% +$758 ﹤0.01% 13607
2022
Q4 		$13.6K Buy
380
+17
+5% +$672 ﹤0.01% 13438
2022
Q3 		$14K Buy
+363
New +$17.2K ﹤0.01% 12173
2022
Q1 		– Sell
-363
Closed -$81K – 13786
2021
Q4 		$81K Sell
363
-434
-54% -$121K ﹤0.01% 12929
2021
Q3 		$276K Sell
797
-246
-24% -$83.4K ﹤0.01% 11229
2021
Q2 		$392K Buy
1,043
+13
+1% +$3.9K ﹤0.01% 10615
2021
Q1 		$320K Buy
1,030
+20
+2% +$7K ﹤0.01% 10705
2020
Q4 		$253K Buy
1,010
+393
+64% +$96.3K ﹤0.01% 9372
2020
Q3 		$114K Sell
617
-443
-42% -$88.1K ﹤0.01% 9193
2020
Q2 		$265K Buy
1,060
+437
+70% +$95.7K ﹤0.01% 8107
2020
Q1 		$113K Sell
623
-727
-54% -$190K ﹤0.01% 8548
2019
Q4 		$563K Buy
+1,350
New +$424K ﹤0.01% 6628

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's DTIL Position: Q1 2026 in Review

Citadel Advisors increased its Precision BioSciences (DTIL) stake by 636% in Q1 2026, buying an estimated $462K and bringing the position to 115,952 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #8703.

Citadel Advisors first reported a position in DTIL in Q1 2019 and has held it in 27 quarters since. The position peaked at $12.6M in Q4 2020. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Citadel Advisors held 115,952 shares of Precision BioSciences worth $638K as of Q1 2026.
  • Citadel Advisors bought 100,204 Precision BioSciences shares in Q1 2026, an estimated $462K.
  • Precision BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8703 holding.
  • Citadel Advisors first reported a position in Precision BioSciences in Q1 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Precision BioSciences position peaked at $12.6M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.